Mazyar Shadman, MD MPH
@mshadman
Associate Professor, Fred Hutch, U of Washington. CLL/Lymphoma. Targeted therapy/Cellular therapy (CAR-T, Transplant). Medical Director, Cellular Immunotherapy
ID: 23896535
12-03-2009 04:19:16
1,1K Tweet
2,2K Followers
1,1K Following
Excited to share our paper in Nature Biotechnology. We've developed a CAR-Enhancer (CAR-E) that enhances the activity and persistence of CAR T-cells. These memory CAR T-cells can re-expand months later. Here's a brief summary: go.nature.com/3SuUgj3
Starting the second #SeattleCellTherapySummit Binaytara Foundation with my co-chair Krish Patel . Looking forward to 2 days of great presentations and discussion with our outstanding speakers and attendees. education.binayfoundation.org/content/2024-s… Fred Hutchinson Cancer Center
Dr. Fong from Fred Hutchinson Cancer Center talking about future directions in immunotherapy for solid tumors. #SeattleCellTherapySummit Binaytara Foundation
Exciting to hear more about TCR therapies for synovial sarcomas from Dr. Elizabeth Loggers at our Seattle Cellular Therapy Summit! Focus on the SPEARHEAD-1 trial that led to the recent FDA approval of the MAGE-A4-directed product afamistresgene for metastatic synovial sarcoma.
Exciting to see the increasing role of immunotherapy in solid tumors #SeattleCellTherapySummit Binaytara Foundation Fred Hutchinson Cancer Center
Outstanding talk on access barriers to CART by Dr. Marc Hoffman University of Kansas. Binaytara Foundation #SeattleCellTherapySummit
Day 2 of #SeattleCellTherapySummit . Starting with myeloma debates Dr. Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 reviewing the CART data. Binaytara Foundation
Dr. Rahul Banerjee, MD, FACP from Fred Hutchinson Cancer Center arguing for NOT using CART in second line for #mmsm #SeattleCellTherapySummit Binaytara Foundation
Debate: should anti-CD19 Abs be used before CD19 CARs? Mehdi Hamadani, MD : yes Matt Lunning D.O. : no What do you think? #SeattleCellTherapySummit Binaytara Foundation
Masterclass with Prof. Mehdi Hamadani, MD on a very controversial topic: are CD19-targeted therapies prior to CD19 CAR T-cell therapy ever a good idea? #SCTS24 Binaytara Foundation
Timely update from Dr. Matthew Frank Stanford Medicine Excited to see the next steps for CD22 CAR T-cell therapy in the pivotal CARGO Therapeutics study, and beyond LBCL! Binaytara Foundation
Which immunotherapy modality is better /most promising for first line #DLBCL? Dr. Neelapu: #CART Dr. Lynch (Ryan Lynch ) : bispecific abs #SeattleCellTherapySummit Binaytara Foundation Fred Hutchinson Cancer Center
CART therapy for T-cell Lymphoma. A great talk by Dr. Rayne Rouce Texas Children's . #SeattleCellTherapySummit Binaytara Foundation
Omg, our paper was selected for the Nature Immunology cover with the amazing "Black Hole Thymus" illustration by DrawImpacts